MCID: ORP003
MIFTS: 60

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15 17
Oropharyngeal Cancer 12 38 56 15
Malignant Neoplasm of Oropharynx 12 74
Oropharyngeal Carcinoma 12 74
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12

Classifications:



Summaries for Oropharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to papilloma and tongue cancer. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, tongue and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and homeostasis/metabolism

Wikipedia : 77 Oropharyngeal cancer is a disease in which cancer form in the tissues of the throat (oropharynx). The... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 papilloma 30.5 CDKN2A KRT14 KRT5 KRT7 TP53
2 tongue cancer 30.2 CDH1 CDKN2A TP53
3 nasopharyngeal carcinoma 29.9 CDH1 CDKN2A EGFR TP53
4 squamous cell carcinoma 29.6 CDH1 CDKN2A EGFR ERBB2 TP53
5 oral cancer 29.6 ADH1C CDH1 CDKN2A EGFR TP53
6 squamous cell carcinoma, head and neck 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
7 adenocarcinoma 29.2 CDH1 CDKN2A EGFR ERBB2 KIT TP53
8 cervical cancer 29.2 CDH1 CDKN2A ERBB2 KRT14 KRT5 TP53
9 esophageal cancer 29.0 CDH1 CDKN2A EGFR ERBB2 TP53 TYMP
10 oral cavity cancer 28.9 CDH1 CRTC1 EGFR ERBB2 MAML2 TP53
11 lung cancer susceptibility 3 28.9 CDH1 CDKN2A EGFR ERBB2 KRT7 TP53
12 in situ carcinoma 28.8 CDH1 CDKN2A EGFR ERBB2 KRT14 KRT5
13 oropharyngeal cancer, childhood 12.2
14 cutaneous telangiectasia and cancer syndrome, familial 11.9
15 bladder squamous cell carcinoma 10.5 CDKN2A TP53
16 spitz nevus 10.5 CDKN2A TP53
17 optic nerve sheath meningioma 10.5 CDKN2A KRT5
18 jejunal cancer 10.5 KIT KRT7
19 cerebral convexity meningioma 10.5 CDH1 TP53
20 intratubular embryonal carcinoma 10.5 KIT KRT7
21 anaplastic oligodendroglioma 10.5 CDKN2A EGFR
22 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR
23 vulvar intraepithelial neoplasia 10.5 KRT7 TP53
24 recurrent respiratory papillomatosis 10.4 EGFR TP53
25 esophageal adenosquamous carcinoma 10.4 CDH1 KRT5
26 sensory organ benign neoplasm 10.4 KRT5 KRT7
27 balloon cell malignant melanoma 10.4 KRT5 KRT7
28 benign mesothelioma 10.4 KRT5 KRT7
29 bile duct mucoepidermoid carcinoma 10.4 KRT5 KRT7
30 middle ear adenoma 10.4 KRT5 KRT7
31 lacrimal system cancer 10.4 MAML2 NFIB
32 cellular ependymoma 10.4 SMUG1 TP53
33 protoplasmic astrocytoma 10.4 SMUG1 TP53
34 colloid adenoma 10.4 SMUG1 TP53
35 large intestine adenocarcinoma 10.4 CDH1 KRT7
36 bartholin's duct cyst 10.4 SMUG1 TP53
37 linitis plastica 10.4 CDH1 KRT7
38 renal pelvis adenocarcinoma 10.4 CDH1 KRT7
39 adenoid squamous cell carcinoma 10.4 CDH1 KRT7
40 malignant acrospiroma 10.4 KRT5 SMUG1
41 fibroepithelial basal cell carcinoma 10.4 KRT14 TP53
42 gallbladder small cell carcinoma 10.4 KRT7 SMUG1
43 tongue squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
44 fallopian tube endometrioid adenocarcinoma 10.4 CDKN2A ERBB2
45 epidermolysis bullosa simplex, autosomal recessive 1 10.4 KRT14 KRT5
46 lichen planopilaris 10.3 KRT14 KRT5
47 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
48 li-fraumeni syndrome 10.3 CDKN2A EGFR TP53
49 teratoma 10.3 KIT KRT7 TP53
50 merkel cell carcinoma 10.3 KIT KRT7 TP53

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

GenomeRNAi Phenotypes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 ACCS CD6 CDH1 CDKN2A ERBB2 KIT

MGI Mouse Phenotypes related to Oropharynx Cancer:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 ADH1C CD6 CDH1 CDKN2A CRTC1 EGFR
2 cellular MP:0005384 10.25 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
3 growth/size/body region MP:0005378 10.25 ADH1C CDH1 CDKN2A CRTC1 EGFR ERBB2
4 endocrine/exocrine gland MP:0005379 10.2 CDH1 CDKN2A CRTC1 EGFR ERBB2 KIT
5 digestive/alimentary MP:0005381 10.13 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
6 immune system MP:0005387 10.07 CD6 CDH1 CDKN2A CRTC1 EGFR KIT
7 craniofacial MP:0005382 10.04 EGFR ERBB2 KIT KRT14 KRT5 NFIB
8 integument MP:0010771 9.97 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
9 neoplasm MP:0002006 9.86 CDH1 CDKN2A EGFR ERBB2 KIT KRT14
10 reproductive system MP:0005389 9.65 CDH1 CDKN2A CRTC1 EGFR ERBB2 KIT
11 pigmentation MP:0001186 9.55 CDKN2A EGFR KIT KRT14 TP53
12 respiratory system MP:0005388 9.17 CDKN2A EGFR ERBB2 KIT KRT14 NFIB

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 441203 84093 2767
3
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
4
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
5
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
6
Nicotine Approved Phase 4,Phase 2,Phase 3,Not Applicable 54-11-5 942 89594
7 sodium fluoride Approved Phase 4 7681-49-4
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Dopamine Agents Phase 4,Phase 2
17 Antidepressive Agents Phase 4,Phase 3,Phase 2
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
19 Antidepressive Agents, Second-Generation Phase 4,Phase 2
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
21 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
22 Dopamine Uptake Inhibitors Phase 4,Phase 2
23 Nicotinic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
24 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
25 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Mitomycins Phase 4,Phase 3
27 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
28 Anti-Infective Agents, Local Phase 4,Not Applicable
29 Listerine Phase 4
30 Fluorides Phase 4,Phase 1,Phase 2,Not Applicable
31 Cariostatic Agents Phase 4
32
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
33
Aldesleukin Approved Phase 3,Phase 2,Phase 1,Not Applicable 85898-30-2, 110942-02-4
34
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
35
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
36
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
37
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
38
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
39
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124
40
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 38904 10339178 498142
41
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
42
Sargramostim Approved, Investigational Phase 3,Phase 2,Not Applicable 123774-72-1, 83869-56-1
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
44
Fluconazole Approved, Investigational Phase 2, Phase 3,Early Phase 1 86386-73-4 3365
45
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
46
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
47
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
48
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
49
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
50
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 522)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
4 Essential Oils With and Without Alcohol: Substantivity and Antiplaque Effect Recruiting NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
5 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Unknown status NCT00181038 Phase 3
6 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
7 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy Unknown status NCT02618993 Phase 3
8 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
9 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection Unknown status NCT02268344 Phase 3
10 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
11 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
12 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
15 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
16 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
17 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
18 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
19 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
20 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
21 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
24 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
25 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
26 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
27 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
28 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
29 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
30 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
31 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
32 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
33 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
34 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
35 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
37 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
38 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
39 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
40 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
41 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
42 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
43 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
44 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
45 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
46 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
47 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
48 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
49 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
50 Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

MalaCards organs/tissues related to Oropharynx Cancer:

42
Lung, Tongue, Lymph Node, Tonsil, Brain, Liver, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

20
The Oropharynx

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 1169)
# Title Authors Year
1
Women with cervical cancer precursor lesions: a high-risk group for human papillomavirus (HPV)-related oropharyngeal cancer? ( 30821615 )
2019
2
Study of Dysphagia in Patients with Advanced Oropharyngeal Cancer Subjected to an Organ Preservation Protocol Based on Concomitant Radiotherapy and Chemotherapy ( 30912631 )
2019
3
Single-item discrimination of quality-of-life-altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing. ( 30633325 )
2019
4
Comparison of psychosocial factors over time among HPV+ oropharyngeal cancer and tobacco-related oral cavity cancer patients. ( 30322742 )
2019
5
In-Office Injection Pharyngoplasty for Velopharyngeal Insufficiency After Oropharyngeal Cancer Treatment. ( 30730561 )
2019
6
HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. ( 30523624 )
2019
7
Volumetric 18 F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. ( 30548704 )
2019
8
Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer. ( 30549345 )
2019
9
HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer. ( 30549362 )
2019
10
Racial disparities and human papillomavirus status in oropharyngeal cancer: A systematic review and meta-analysis. ( 30561088 )
2019
11
Chronic opioid use in patients undergoing treatment for oropharyngeal cancer. ( 30613983 )
2019
12
Survival impact of treatment delays in surgically managed oropharyngeal cancer and the role of human papillomavirus status. ( 30615247 )
2019
13
Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy. ( 30616786 )
2019
14
A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer. ( 30625409 )
2019
15
Effect of treatment modality on chronic opioid use in patients with T1/T2 oropharyngeal cancer. ( 30629308 )
2019
16
Occupational exposure to petroleum-based and oxygenated solvents and oral and oropharyngeal cancer risk in men: A population-based case-control study in France. ( 30658217 )
2019
17
Correlation between the duration of locoregional control and survival in T1-T2 oropharyngeal cancer patients. ( 30666440 )
2019
18
Developing case-finding algorithms for second events of oropharyngeal cancer using administrative data: A population-based validation study. ( 30706597 )
2019
19
Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy. ( 30715409 )
2019
20
The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. ( 30719797 )
2019
21
Lymphocyte Telomere Length Predicts Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy. ( 30721961 )
2019
22
Gender-neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness. ( 30722999 )
2019
23
FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation. ( 30758660 )
2019
24
Authors' response letter: Quality of life in oropharyngeal cancer: a structured review of the literature. ( 30762140 )
2019
25
Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus. ( 30771020 )
2019
26
Concurrent chemotherapy in oropharyngeal cancer: Cisplatin wins. ( 30774757 )
2019
27
Correction to: Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study. ( 30808410 )
2019
28
Regional Radiation Therapy for Oropharyngeal Cancer in the HPV Era. ( 30827450 )
2019
29
Trends in Reporting of Swallowing Outcomes in Oropharyngeal Cancer Studies: A Systematic Review. ( 30847548 )
2019
30
Primary surgical treatment versus salvage surgery: Results of free flap reconstruction performed in 100 patients with oropharyngeal cancer. ( 30851896 )
2019
31
Behavioral analysis of HPV+ oropharyngeal cancer: Do you know your patients? ( 30853084 )
2019
32
Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process? ( 30877351 )
2019
33
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. ( 30887169 )
2019
34
The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus-Positive Versus Human Papillomavirus-Negative Patients With Oropharyngeal Cancer. ( 30889002 )
2019
35
Swallowing Function in Survivors of Oropharyngeal Cancer Is Associated With Advanced T Classification. ( 30913911 )
2019
36
Influence of municipal socioeconomic indices on mortality rates for oral and oropharyngeal cancer in older adults in the State of São Paulo, Brazil. ( 30916141 )
2019
37
The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. ( 30191960 )
2019
38
Does p16+ Predict a Favorable Prognosis for Oropharyngeal Cancer? Risk Factors for Treatment Failure for Patients Who Underwent Surgery-Based Therapy. ( 30276645 )
2019
39
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. ( 30449625 )
2019
40
Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. ( 29100700 )
2018
41
Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. ( 29243245 )
2018
42
Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ( 29969771 )
2018
43
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. ( 29948260 )
2018
44
Bayesian model and spatial analysis of oral and oropharynx cancer mortality in Minas Gerais, Brazil. ( 29267820 )
2018
45
Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. ( 29496037 )
2018
46
Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. ( 29961581 )
2018
47
Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer - A retrospective dosimetry review and feasibility planning study. ( 29290281 )
2018
48
HPV status, like politics, is local-evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer. ( 29788169 )
2018
49
A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. ( 30206020 )
2018
50
Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. ( 29149493 )
2018

Variations for Oropharynx Cancer

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 CDH1 CDKN2A EGFR ERBB2 KIT TP53
2 12.52 CDH1 CDKN2A EGFR ERBB2 KIT TP53
3
Show member pathways
12.45 CDH1 CDKN2A EGFR ERBB2 TP53
4
Show member pathways
12.4 CDH1 CDKN2A EGFR ERBB2 KIT TP53
5 12.33 CDKN2A EGFR ERBB2 TP53
6
Show member pathways
12.17 CDH1 EGFR ERBB2 KIT TYMP
7
Show member pathways
11.69 EGFR ERBB2 KIT
8 11.61 KRT14 KRT5 TP53
9 11.55 CDKN2A ERBB2 TP53
10 11.53 CDH1 EGFR ERBB2
11 11.32 CDKN2A EGFR TP53
12 11.28 ERBB2 MYBL1 NFIB TP53
13 11.07 EGFR ERBB2 KIT TP53
14 11.04 CDH1 EGFR ERBB2
15 10.96 CDH1 CDKN2A EGFR ERBB2 TP53 TYMP
16 10.84 CDH1 EGFR ERBB2 KIT TYMP

GO Terms for Oropharynx Cancer

Cellular components related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 8.8 KRT14 KRT5 KRT7

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.8 EGFR MYBL1 TP53 TYMP
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 EGFR ERBB2 KIT
3 positive regulation of gene expression GO:0010628 9.65 CDKN2A ERBB2 KIT PLAG1 TP53
4 positive regulation of MAP kinase activity GO:0043406 9.5 EGFR ERBB2 KIT
5 replicative senescence GO:0090399 9.48 CDKN2A TP53
6 hemidesmosome assembly GO:0031581 9.46 KRT14 KRT5
7 tongue development GO:0043586 9.43 EGFR KIT
8 somatic stem cell division GO:0048103 9.4 CDKN2A KIT
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.37 EGFR TP53
10 positive regulation of transcription by RNA polymerase II GO:0045944 9.23 CDKN2A CRTC1 EGFR MAML2 MYBL1 NFIB
11 negative regulation of ERBB signaling pathway GO:1901185 9.16 EGFR ERBB2
12 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 TP53
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 EGFR ERBB2 KIT
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR ERBB2 KIT

Sources for Oropharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....